Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vermillion Inc (VRML)

Vermillion Inc (VRML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vermillion Inc 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 USA

www.vermillion.com P: 512-519-0400

Description:

Vermillion, Inc. is engaged in the discovery, development and commercialization of novel diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company has diagnostic programs in oncology, hematology, cardiology and women's health. Its tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Vermillion also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others. Its lead product includes the OVA1 ovarian tumor triage test, which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. In addition to the OVA1 Test, Vermillion has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. Vermillion, Inc. is based in Fremont, California.

Key Statistics

Overview:

Market Capitalization, $K 389,512
Shares Outstanding, K 97,378
Annual Sales, $ 4,540 K
Annual Net Income, $ -15,240 K
Last Quarter Sales, $ 1,220 K
Last Quarter Net Income, $ -3,710 K
60-Month Beta 3.47
% of Insider Shareholders 4.40%
% of Institutional Shareholders 18.09%
Float, K 93,093
% Float 95.60%

Growth:

1-Year Return 247.83%
3-Year Return 133.92%
5-Year Return 93.24%
5-Year Revenue Growth 80.16%
5-Year Earnings Growth 66.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 05/14/20
Earnings Per Share ttm -0.17
EPS Growth vs. Prev Qtr -33.33%
EPS Growth vs. Prev Year 20.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 04/02/08

VRML Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -155.25%
Return-on-Assets % -103.47%
Profit Margin % -335.68%
Debt/Equity 0.20
Price/Sales 92.91
Price/Cash Flow N/A
Price/Book 73.46
Book Value/Share 0.05
Interest Coverage -255.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar